Evidence map›Paper›PMID 40672769›Full record

ArticleSovremennye tekhnologii v meditsine2025

Regulation of Ferroptosis in Human Macrophage by Nitric Oxide Donors.

I I Vlasova, M D Yurkanova, A A Zolotopup, T O Klyucherev, P S Timashev

Abstract read
In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

I I VlasovaLeading Researcher, Department of Modern Biomaterials; I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya St., Moscow, 119991, Russia.
M D YurkanovaLaboratory Assistant, Laboratory of Clinical Smart Nanotechnologies; I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya St., Moscow, 119991, Russia.
A A ZolotopupLaboratory Assistant, Laboratory of Clinical Smart Nanotechnologies; I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya St., Moscow, 119991, Russia.
T O KlyucherevJunior Researcher, Laboratory of Clinical Smart Nanotechnologies; I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya St., Moscow, 119991, Russia.
P S TimashevProfessor, Institute of Regenerative Medicine; Scientific Director, Scientific and Technological Park of Biomedicine; I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya St., Moscow, 119991, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis is a programmed form of cell death in which iron-dependent lipid peroxidation is the main feature. Macrophages are the major cells of the immune system, they function in a pro-oxidative environment, so the study of their susceptibility to ferroptosis and the search for approaches to its regulation are important. Materials and Methods: RSL3 and ML-162, inhibitors of glutathione peroxidase 4 (GPX4), and erastin, an inhibitor of cystine/ glutamate transport, were used to induce ferroptosis in THP-1 macrophages. The progression of ferroptosis was monitored using three independent methods: reduction of Alamar blue by live cells, measurement of lactate dehydrogenase in the medium, and the LIVE/DEAD assay. Ferroptotic cell death was proven by using the specific inhibitor ferrostatin-1 and by detecting lipid oxidation in cells using the BODIPY 581/591 C11 fluorescent probe. Results: RSL3 and ML-162 dose-dependently induced ferroptosis in cells. THP-1 macrophage ferroptosis is a slow process and begins ~5 h after inducer addition. Erastin was a weak ferroptosis inducer; however, it enhanced ferroptosis induced by GPX4 inhibitors. We compared the ability of two NO donors with different half-lives to affect THP-1 macrophage ferroptosis: DEA NONOate (2 min) and DTPA NONOate (3 h). Donors were added either once after the inducer at a concentration of 100-120 μM or repeatedly until reaching the final concentration. DEA had no effect on THP-1 macrophage ferroptosis, whereas DPTA completely inhibited ferroptosis. Conclusion: DTPA, being an NO donor with a half-life of 3 h at 37°С, can be used to inhibit ferroptosis in THP-1 macrophages, which develops within 17-19 h. Therefore, there are mechanisms of prolongation of NO action in cells that should be studied to use NO donors for regulation of cellular ferroptosis.

Indexed as

FerroptosisMacrophagesNitric Oxide DonorsCarbolinesHumansLipid PeroxidationPiperazinesTHP-1 CellsCarbolinesNitric Oxide DonorsPiperazinesRSL3 compoundferroptosisnitric oxide donorsTHP-1 macrophages

Identifiers

PMID40672769
PMCPMC12261289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.